YUCAIPA, Calif., June 12, 2009 (GLOBE NEWSWIRE) -- Ingen Technologies, Inc. (Pink Sheets:IGNT - News) a leading Medical Device Manufacturer focused in the $8 Billion global Respiratory Markets for the growing ageing population and emerging markets for Home (DME), Hospital and Aviation Industries announced today that the company was notified by Legend Medical Devices that the first production sample product of the Oxyview-Cannula will arrive next week.
Mr. Bill Liang of Legend Medical Devices notified Ingen that the production samples will arrive next week. The company plans on manufacturing an immediate 10,000 Oxyview-Cannula's with first deliveries available for sale before the end of June-2009. The Oxyview is manufactured by Ingen Technologies in California-USA, and bulk product will be sent to China where Legend Medical Devices will attach and package the Oxyview to various nasal-cannulas under the Ingen-Logo and shipped back to Ingen. The company was recently issued patents in China, with pending patents in Europe, Japan, and Canada. This is in addition to the previously issued patents for the USA.
There are a recorded 23 million patients in the U.S. using home oxygen therapy, and all of them, not including hospitalized patients, use several nasal cannula's each month. There are an estimated 600 million patients worldwide that require home oxygen therapy. The current market for the nasal cannula has a cost range of $2-$6 per cannula, and is used for approximately 10 days before disposed. These current cannulas do not include a built-in flow meter. The new disposable Oxyview-Cannula will include the nasal cannula and the Ingen Oxyview flow-meter attached at a cost of $4.75. Typically the nasal cannula is replaced 3-4 times each month because it builds up bacteria and moisture. The average list price for a nasal cannula is $5.75, however. The DME provider is responsible to include the cannula along with the other oxygen equipment reimbursable at a flat monthly rate from Medicare. There are several advantages to using the new Oxyview-Cannula, inclusive of allowing the patient to be assured that they are receiving the prescribed dosage of oxygen where it is needed the most and trouble-shooting equipment problems over the phone with the oxygen supplier preventing an on-site service call. Without the Oxyview-Cannula, patients cannot confirm oxygen flow nearest to them, nor can they actually be assured that the equipment is functioning properly. "The new Oxyview-Cannula should improve home oxygen therapy and decrease costs associated to unnecessary service call," stated Chris Wirth, COO of Ingen Technologies.
The nasal cannula (NC) is a device used to deliver supplemental oxygen to a patient or person in need of extra oxygen. This device consists of a plastic tube which fits behind the ears, and a set of two prongs which are placed in the nostrils. Oxygen flows from these prongs. The nasal cannula is connected to an oxygen tank, a portable oxygen generator, or a wall connection in a hospital via a flow meter. The nasal cannula carries 1-6 liters of oxygen per minute. There are also infant or neonatal nasal cannulas which carry less than one liter per minute; these also have smaller prongs. The oxygen fraction provided to the patient ranges roughly from 24% to 35%. The nasal cannula was invented by Wilfred Jones and patented in 1949 by his employer, BOC.
The company has been selling Oxyview as an individually packaged respiratory product, and has now developed a disposable and more affordable Oxyview flow meter that will be attached and prepackaged to a variety of nasal cannula products for the 23M home oxygen patients in the USA and 600M patients worldwide. The company will sell the new Oxyview-Cannula under the Ingen logo. The potential market size for the new Oxyview-Cannula is a conservative estimate of $200M per year in the U.S. and $150M per year outside the U.S..
"As mentioned in a previous release, the new disposable Oxyview-Cannula should revolutionize the home oxygen therapy market worldwide. There is nothing else in comparison, and Ingen will sell the new nasal cannula at competitive prices starting this month. For the same price, a patient can choose to either have a nasal cannula with or without a flow-meter. I can't imagine that the patient would choose a nasal cannula without the Oxyview included," stated Scott Sand, CEO and Chairman of Ingen Technologies.
About Oxyview:
Oxyview is a proprietary medical device with U.S. issued patents that stands alone in an increasing patient home oxygen therapy market while there are 23 million patients diagnosed with chronic obstructive pulmonary disease (COPD) in the United States, according to the World Health Organization, and another 12 million patients that are undiagnosed in the U.S. COPD is the fifth leading cause of death in the US and there are 600 million COPD patients worldwide where in most cases, COPD is either the first or second leading cause of death in other countries. The majority of COPD patients require continued home oxygen therapy, which includes all of the required equipment supplied by the home (DME) provider. With the new regulations for oxygen reimbursement in the U.S., the home (DME) providers need to cut costs to stay in business. Oxyview provides a substantial savings as a result of decreasing the number of service calls for the home (DME) provider. Oxyview is a pneumatic metering device that displays oxygen flow near the patient. The Oxyview flow meter easily and quickly installs on to the oxygen tubing nearest the patient where oxygen flow matters the most. Without the Oxyview, patients cannot confirm oxygen flow, and as a result there is an increase in anxiety and the patient calls the home (DME) provider with concerns. Oxyview also allows the home (DME) provider to trouble-shoot other equipment problems over the telephone which eliminates an on-site visit with the patient. More important, the Oxyview provides the patient with more assurance that they are receiving adequate and prescribed oxygen flow. The Oxyview costs less than a single service call.
www.ingen-tech.com
The Ingen Technologies, Inc. logo is available at http://www.globenewswire.com/newsroom/prs/?pkgid=2472
Safe Harbor for Forward-Looking Statements: This news release includes forward-looking statements. While these statements are made to convey to the public the company's progress, business opportunities and growth prospects, readers are cautioned that such forward-looking statements represent management's opinion. Whereas management believes such representations to be true and accurate based on information and data available to the company at this time, actual results may differ materially from those described. The company's operations and business prospects are always subject to risk and uncertainties. Important factors that may cause actual results to differ are and will be set forth in the company's periodic filings with the U.S. Securities and Exchange Commission.
No comments:
Post a Comment